SW626Homo sapiens (Human)Cancer cell line
Also known as: SW 626, SW-626, SWS-26
Quick Overview
SW626 is a human ovarian cancer cell line used in cancer research.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_1725 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Ovary[UBERON:UBERON_0000992] |
Donor Information
| Age | 46 |
|---|---|
| Age Category | Adult |
| Sex | Female |
Disease Information
| Disease | Colon adenocarcinoma |
|---|---|
| Lineage | Bowel |
| Subtype | Colon Adenocarcinoma |
| OncoTree Code | COAD |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-001399_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | TP53 | p.Gly262Val (c.785G>T) | Homozygous | - | Unknown, Unknown |
| MutationSimple | SMAD4 | p.Asp351His (c.1051G>C) | Homozygous | - | from parent cell line Caco-2 |
| MutationSimple | KRAS | p.Gly12Val (c.35G>T) | Heterozygous | Acquired | Unknown, Unknown |
| MutationSimple | APC | p.Arg976fs*9 (c.2926_2927insA) | Homozygous | - | Unknown, Unknown, Unknown |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Pan-cancer proteomic map of 949 human cell lines.";
Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.
Cancer Cell 40:835-849.e8(2022).
Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.
Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.
Nature 568:511-516(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
A landscape of pharmacogenomic interactions in cancer.";
Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
Cell 166:740-754(2016).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Int. J. Oncol. 46:2389-2398(2015).
BRCA1/2 mutation analysis in 41 ovarian cell lines reveals only one functionally deleterious BRCA1 mutation.
Mills G.B., Hennessy B.T.
Mol. Oncol. 7:567-579(2013).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
FGFR2 mutations are rare across histologic subtypes of ovarian cancer.
Campbell I.G., Pollock P.M.
Gynecol. Oncol. 117:125-129(2010).
Mutations of the BRAF gene in human cancer.";
Marshall C.J., Wooster R., Stratton M.R., Futreal P.A.
Nature 417:949-954(2002).
Searching for microsatellite mutations in coding regions in lung, breast, ovarian and colorectal cancers.
Minna J.D.
Oncogene 20:1005-1009(2001).
Evidence for the colonic origin of ovarian cancer cell line SW626.";
Furlong M.T., Hough C.D., Sherman-Baust C.A., Pizer E.S., Morin P.J.
J. Natl. Cancer Inst. 91:1327-1328(1999).
Mutation of the PTEN tumor suppressor gene is not a feature of ovarian cancers.
Berchuck A., Futreal P.A.
Gynecol. Oncol. 70:13-16(1998).
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).